Rankings
▼
Calendar
DNLI Q3 2025 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena
DNLI
Denali Therapeutics Inc.
$3B
Q3 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$0
Gross Profit
$0
Operating Income
-$137M
Net Income
-$127M
EPS (Diluted)
$-0.74
QoQ Revenue Growth
NaN%
Cash Flow
Operating Cash Flow
-$107M
Free Cash Flow
-$106M
Stock-Based Comp.
$0
Balance Sheet
Total Assets
$1.1B
Total Liabilities
$129M
Stockholders' Equity
$926M
Cash & Equivalents
$91M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$0
$0
—
Gross Profit
$0
$0
—
Operating Income
-$137M
-$123M
-11.6%
Net Income
-$127M
-$107M
-18.4%
← FY 2025
All Quarters
Q4 2025 →